THE INTRADAY

IFF · Company KPIs

IFF (IFF) KPIs

Comparable currency neutral sales growth, Comparable currency neutral adjusted operating EBITDA growth. As reported in SEC filings, with the source line for each figure.

Comparable currency neutral sales growth

6% for the period ended Jun 30, 2026

Jun 30, 2025: 3%Sep 30, 2025: 0%Dec 31, 2025: 1%Mar 31, 2026: 3%Jun 30, 2026: 6%Jun 30, 2025Jun 30, 2026

The filings read for this page do not define this measure.

Comparable currency neutral sales growth, as first reported, with the line it was read from
Period endedFigureFiling text
Jun 30, 20266%% Change - Currency Neutral · 6% · 6% · 0.0%8-K filed 2026-08-04
Mar 31, 20263%% Change - Currency Neutral · 3% · 8% · 1.1%8-K filed 2026-05-05
Dec 31, 20251%On a comparable basis2, currency neutral sales1 increased 1% versus the prior year period, against a strong 6% year ago comparable, led by mid-single digit growth in Health & Biosciences and Scent and a low-single digit performance in Taste.8-K filed 2026-02-11
Sep 30, 20250%Consolidated · (8)% · 0% · (9)% · 7%8-K filed 2025-11-04
Jun 30, 20253%On a comparable basis2, currency neutral sales1 increased 3% versus the prior-year period led by broad-based growth including mid-single digit performances in Taste and Health & Biosciences.8-K filed 2025-08-05

Comparable currency neutral adjusted operating EBITDA growth

6% for the period ended Jun 30, 2026

Jun 30, 2025: 6%Sep 30, 2025: 7%Dec 31, 2025: 7%Mar 31, 2026: 8%Jun 30, 2026: 6%Jun 30, 2025Jun 30, 2026

The filings read for this page do not define this measure.

Comparable currency neutral adjusted operating EBITDA growth, as first reported, with the line it was read from
Period endedFigureFiling text
Jun 30, 20266%% Change - Currency Neutral · 6% · 6% · 0.0%8-K filed 2026-08-04
Mar 31, 20268%% Change - Currency Neutral · 3% · 8% · 1.1%8-K filed 2026-05-05
Dec 31, 20257%On a comparable basis2, currency neutral adjusted operating EBITDA1 increased 7% led primarily by productivity gains.8-K filed 2026-02-11
Sep 30, 20257%Consolidated · (8)% · 0% · (9)% · 7%8-K filed 2025-11-04
Jun 30, 20256%On a comparable basis2, currency neutral adjusted operating EBITDA1 improved 6% versus the prior-year period, led by volume growth, favorable net pricing and productivity.8-K filed 2025-08-05

Reading notes

Figures are shown as first reported. If a later filing prints a different figure for the same period, both appear. A figure marked ≈ or shown in words is how the company itself states it, not an estimate of ours. Companies change definitions over time, so compare periods with the quoted definition in mind. Periods that failed our checks are left out, so gaps are expected.